Download PDF
Synlett 2003(2): 0256-0258
DOI: 10.1055/s-2003-36780
LETTER
© Georg Thieme Verlag Stuttgart · New York

An Efficient Route to Novel 2-(Salicylmethylidine)imidazolidines and (Salicylmethylidene)hexahydropyrimidines through Reactions of 2-(N-Methylanilino)-3-formylchromone with Aliphatic Diamines

Gurmit Singh, Gurpinder Singh, M. P. S. Ishar*
Department of Pharmaceutical Sciences, Guru Nanak Dev University, Amritsar - 143005, Punjab, India
Fax: +91(183)258820; e-Mail: mpsishar@rediffmail.com;
Further Information

Publication History

Received 23 November 2002
Publication Date:
22 January 2003 (online)

    Permissions and Reprints All articles of this category

Abstract

Contrary to the reactions of 2-(N-methylanilino)-3-formylchromones (3) with aliphatic/aromatic primary amines, including o-phenylenediamine, which involve nucleophilic substitution at C2 and/or condensation with the 3-formyl function, the reactions of 3 with aliphatic diamines such as ethylenediamine and 1,3-diaminopropane proceed through sequential attack by both amino functions at C2 in 3. The latter reactions afford, through nucleophilic substitution of the N-methylanilino moiety followed by chromone ring opening, novel potentially biologically active, 2-(formyl-salicyl-methylidene)imidazolidines (7a-c) and 2-(formyl-salicyl-methylidene)hexahydropyrimidines (7d-f) in high yields.

Key words

imidazolidines - hexahydropyrimidines - chromones - nucleophilic substitution - diamines

    References

  • 1a Silverman RB. In Organic Chemistry of Drug Design and Drug Action   Academic Press Inc.; San Diego: 1992.  Chap. 2. p.4-50  
  • 1b Comprehensive Medicinal Chemistry   Vol. 4:  Hansch C. Sammes PG. Taylor JB. Pergamon Press; London: 1990. 
  • 1c Musser JH. In Medicinal Chemistry for the 21st Century   Wermuth CG. Blackwell Scientific Publications; Oxford: 1992.  p.25-38  
  • 1d Austel V. In Modern Drug Research   Martin YC. Kutter E. Austel V. Marcell Dekker; New York: 1989.  p.243-307  
  • 1e Burger A. In Burgers Medicinal Chemistry and Drug Discovery   5th ed.,Vol. 1:  Wolf ME. John Wiley and Sons; New York: 1996.  Chap. 1. p.3-8  
    Search in Google Scholar
  • 2a Thompson LA. Ellman JA. Chem. Rev.  1996,  96:  555 
    CrossrefSearch in Google Scholar
  • 2b Fruchtel JS. Jung G. Angew. Chem., Int. Ed. Engl.  1996,  35:  17 
    CrossrefSearch in Google Scholar
  • 2c Nezfi A. Ostresh JM. Houghten RA. Chem. Rev.  1997,  97:  449 
    CrossrefSearch in Google Scholar
  • 2d Robert GF. J. Comb. Chem.  2000,  2:  195 
    CrossrefSearch in Google Scholar
  • 3a Comprehensive Medicinal Chemistry   Vol. 6.:  Hansch C. Sammes PG. Taylor JB. Pergamon Press; London: 1990. 
  • 3b Lednicer D. Strategies for Organic Drug Synthesis and Design   John Wiley and Sons; New York: 1998.  p.185-241  
  • 3c Timmerman PBM. Smith RD. In Burgers Medicinal Chemistry and Drug Discovery   5th ed.,Vol. 2:  Wolf ME. John Wiley and Sons; New York: 1996.  p.265-321  
    Search in Google Scholar
  • 3d Michael MC. Schafers R. J. Cardiovasc. Pharmacol.  1992,  29 (Suppl .4):  S24 
    Search in Google Scholar
  • 3e Safar ME. Am. J. Med.  1989,  87 (Suppl. 3C):  24S 
    Search in Google Scholar
  • 3f Robinson CP. Drugs Today  1988,  24:  557 
    Search in Google Scholar
  • 3g Timmerman PBM. Van Zwieten PA. Eur. J. Med. Chem.  1980,  15:  233 
    Search in Google Scholar
  • 3h Houston MC. Prog. Cardiovasc. Dis.  1981,  23:  337 
    Search in Google Scholar
  • 3i Stump DC. Macfarlane DE. J. Lab. Clin. Biol. Res.  1983,  102:  779 
    Search in Google Scholar
  • 3j U’Prichard DC. Prog. Clin. Biol. Res.  1981,  71:  53 
    Search in Google Scholar
  • 3k Rout B. Leclerc G. Bull. Soc. Chim. Fr.  1979,  520 
  • 3l Haron DWG. Shank RG. Lancet  1981,  1:  351 
    Search in Google Scholar
  • 3m Haron DWG. Shank RG. Eur. Heart J.  1985,  6:  722 
    Search in Google Scholar
  • 3n Heidenreich O. Fuelgraff G. Baumeister L. Schmiz K. Arch. Expt. Pathol. Pharmakol.  1964,  249:  432 
    Search in Google Scholar
  • 3o Heidenreich O. Baumeister L. Fuelgraff G. Keller P. Kook Y. Arch. Int. Pharmadyn.  1965,  156:  348 
    Search in Google Scholar
  • 3p Outt PE. Ares JJ. Roberts GE. Wang X. Cupps TL. Wireko FC. J. Org. Chem.  1998,  63:  5762 
    Search in Google Scholar
  • 3q Rosatti GF. Polleto MG. Farmaco  1966,  21:  204 
    Search in Google Scholar
  • 3r Campbell WR. Polter DE. Prog. Neuro Psych. Biol. Psych.  1994,  18:  1051 
    Search in Google Scholar
  • 3s Peckkhold JC. Curr. Ther. Res.  1980,  27:  111 
    Search in Google Scholar
  • 4a Timmerman PBM. Van Zwieten PA. J. Med. Chem.  1977,  20:  1636 
    Search in Google Scholar
  • 4b Timmerman PBM. Van Zwieten PA. Eur. J. Med. Chem.  1980,  15:  233 
    Search in Google Scholar
  • 4c Velly J. J. Pharmacol.  1977,  8:  351 
    Search in Google Scholar
  • 4d Kamitani T. Kamamoto M. Truzioka K. Terai T. Minovu O. Ono T. Kikuchi K. Kumada S. Jpn. J. Pharmacol.  1985,  39:  251 
    Search in Google Scholar
  • 4e Biedermann J, Borbe H, Graf E, Hirlboll G, and Prop G. inventors; German Patent  .  DE 3,407.509; Chem. Abstr., 1986, 104, 15084v
  • 5 Yu Y. Ostresh JM. Houghten RA. J. Org. Chem.  2002,  67:  3138 
    CrossrefPubMedSearch in Google Scholar
  • 6a Ishar MPS. Kumar K. Singh R. Tetrahedron Lett.  1998,  39:  6547 
    CrossrefSearch in Google Scholar
  • 6b Ishar MPS. Kumar K. Tetrahedron Lett.  1999,  40:  175 
    CrossrefSearch in Google Scholar
  • 6c Ishar MPS. Singh G. Kumar K. Singh R. Tetrahedron  2000,  56:  7817 
    CrossrefSearch in Google Scholar
  • 6d Singh G. Singh R. Girdhar NK. Ishar MPS. Tetrahedron  2002,  58:  2471 
    CrossrefSearch in Google Scholar
  • 6e

    Singh, G.; Singh, L.; Ishar, M. P. S. Tetrahedron 2002, 58, in press.
    Crossref
  • 8a

    2-(Formyl-salicyl-methylidene)imidazolidine (7a): Colorless crystalline solid, mp 265-266 °C (acetone). UV (MeOH): 362.4, 263, 228.4 nm. IR (KBr): 3310 (s), 3118 (b), 1672 (HC=O), 1625 (C=O), 1602, 1533, 1452, 1434
    cm-1. 1H NMR (200 MHz, DMSO-d 6): δ = 9.18 (overlapping singlets, 2 H, NH, OH), 8.94 (s, 1 H, HC=O), 8.30 (s, 1 H, NH), 7.22 (dt, 1 H, J = 8.61, 2.35 Hz, C4′-H), 7.03 (dd, 1 H, J = 8.29 Hz, 1.69, C6′-H), 6.80-6.76 (m, 2 H, C3′-H and C5′-H), 3.63 (s, 4 H, N-CH2 × 2). MS: m/z (%) = 230 (1) [M+ - 2], 214 (1.5), 213 (3), 205 (5), 204 (29), 203 (8), 84 (100), (Found: C, 62.28; H, 5.11; N, 12.34. C12H12N2O3 requires C, 62.06; H, 5.21; N 12.06 %).
    2-[(5-Chlorosalicyl)-formyl-methylidene]imidazolidine (7b): Colorless crystalline solid, mp 271-272 °C (acetone). UV (MeOH): 262, 223 nm. IR (KBr): 3350 (b), 3100 (b), 1668 (HC=O), 1619 (C=O), 1595, 1556, 1532, 1541 cm-1. 1H NMR (300 MHz, DMSO-d 6): δ = 9.75 (br s, 1 H, OH), 9.21 (br s, 2 H, NH × 2), 9.10 (s, 1 H, CHO), 7.15 (dd, 1 H, J = 8.61, 2.35 Hz, C4′-H), 7.08 (d, 1 H, J = 2.30 Hz, C6′-H), 6.85 (d, 1 H, J = 8.69 Hz, C3′-H), 3.77 (s, 4 H, N-CH2 × 2). 13C NMR (75 MHz, DMSO-d 6): δ = 190.43 (C=O), 188.06 (CHO), 163.43 (C2), 152.69 (C2), 129.72 (C1′), 129.31 (CH), 127.67 (CH), 122.59 (C5′), 117.25 (CH), 99.65 (quat.), 42.43 (N-CH2). Mass (FAB+): m/z (%) = 269 (31) [(M + H)+ + 2 (37Cl)], 268 (22) [(M + H)+ + 1], 267 (100) [(M + H)+ for 35Cl], 266 (36), 249 (37), 155 (18), 154 (93), 140 (30), 139 (24), 138 (45), 137 (68), (Found: C, 53.87; H, 4.01; N, 10.81. C12H11N2O3Cl requires C, 54.05; H, 4.16; N 10.50%].
    2-[Formyl-(5-Methylsalicyl)-methylidene]imidazolidine (7c): Colorless crystalline solid, mp 267-269 °C (acetone). UV (CHCl3): 324, 287, 267.5, 256 nm. IR (KBr): 3290 (b), 3060 (b), 1660 (HC=O), 1622 (C=O), 1580, 1520, 1500, 1428, 1392, 1378, 1331, 1288, 1261 cm-1. 1H NMR (200 MHz, CDCl3-DMSO-d 6, 8:2): δ = 9.75 (br s, 1 H, -OH), 9.33 (s, 1 H, CHO), 9.24 (br s, 2 H, NH × 2), 7.10-7.06 (m, 2 H, arom.-Hs), 6.80 (d, 1 H, J = 8.09 Hz, C3′-H), 3.82 (s, 4 H, N-CH2 × 2), 2.26 (s, 3 H, Ar-CH3). MS: m/z (%) = 245 (8) [M+ - 1], 243 (9), 188 (11), 169 (100), 111 (60), 94 (41), 83 (47), 71 (78), (Found: C, 63.18; H, 5.51; N, 11.64. C13H14N2O3 requires C, 63.40; H, 5.73; N 11.38%).
    2-(Formyl-salicyl-methylidene)hexahydropyrimidine (7d): Colorless crystalline solid (219 mg, 89%), mp 176-177 °C (acetone). UV (MeOH): 332, 262.5, 219 nm. IR (KBr): 3400 (b), 3090 (b), 2755, 1656 (HC=O), 1642 (C=O), 1604, 1572, 1401, 1365, 1338, 1326, 1302, 1273, 1245, 1224, 1147 cm-1: 1H NMR (200 MHz, DMSO-d 6): δ = 10.64 (br s, 2 H, NH and OH), 9.83 (br s, 1 H, NH), 9.13 (s, 1 H, CHO), 7.37 (dt, 1 H, J = 7.02, 1.51 Hz, C4′-H), 7.24 (br d, 1 H, J = 6.42 Hz, C6′-H), 7.07-6.99 (m, 2 H, C5′-H and C3′-H), 3.61 (b, 4 H, N-CH2 × 2), 2.13-2.08 (m, 2 H, -CH2). 13C NMR (50 MHz, DMSO-d 6): δ = 194.25 (C=O), 189.70 (CHO), 158.82 (C2), 153.70 (C2′), 130.10 (CH), 128.98 (C1′), 128.80 (CH), 119.25 (CH), 115.80 (CH), 100.51 (quat.), 37.78 (N-CH2), 19.06 (CH2). MS: m/z (%) = 246 (15) [M+], 228 (69) [M+ - 18], 172 (42), 108 (100), (Found: C, 63.26; H, 5.48; N, 11.11. C13H14N2O3 requires C, 63.40; H, 5.73; N 11.38%).
    2-[(5-Chlorosalicyl)-formyl-methylidene]hexahydro-pyrimidine (7e): Colorless crystalline solid, mp 169-171 °C (acetone). UV (CHCl3): 330, 269.5, 251 nm. IR (KBr): 3490 (b), 3100 (b), 1657 (HC=O), 1635 (C=O), 1611, 1535, 1468, 1430, 1418, 1358, 1322, 1282, 1260, 1240, 1215 cm-1. 1H NMR (200 MHz, CDCl3-DMSO-d 6, 8:2): δ = 10.46 (br, 2 H, NHs), 9.02 (s, 1 H, CHO), 7.28-7.01 (m, 2 H, arom.-Hs), 6.80 (d, 1 H, J = 8.58 Hz, C3′-H), 3.44-3.41 (m, 4 H, N-CH2 × 2), 2.00-1.93 (m, 2 H, -CH2). MS: m/z (%) = 282 [(M+ + 2 (37Cl)], 281 (1.9), 280 (10)[M+ (35Cl)], 279 (35), 264 (8), 262 (31), 254 (14), 252 (30), 247 (5), 246 (3), 245 (18), 152 (4), 150 (18), 172 (5), 171 (23), 169 (70), 99 (15), 98 (100), 97 (14), (Found: C, 55.84; H, 4.81; N, 9.63. C13H13N2O3Cl requires C, 55.62; H, 4.67; N, 9.98%).
    2-[Formyl-(5-methylsalicyl)-methylidene]hexahydro-pyrimidine (7f): Creamy yellow crystalline solid, mp 160-162 °C (acetone). UV (CHCl3): 332, 307, 271.5, 256.5 nm. IR (KBr): 3360 (b), 3040 (b), 1658 (HC=O), 1633 (C=O), 1606, 1571, 1470, 1451, 1390, 1361, 1280 cm-1. 1H NMR (200 MHz, CDCl3): δ = 10.51 (br, 2 H, NHs), 9.35 (s, 1 H, CHO), 7.14-7.08 (m, 2 H, arom -Hs), 6.84 (d, 1 H, J = 8.26 Hz, C3′-H), 3.48-3.41 (s, 4 H, N-CH2 × 2), 2.24 (s, 3 H, Ar-CH3), 2.05-1.97 (m, 2 H, CH2). 13C NMR (50 MHz, CDCl3): δ = 196.66 (C=O), 189.78 (CHO), 159.99 (C2), 156.83 (C2′), 133.41 (CH), 131.71 (CH), 127.11 (C1′), 122.16 (C5′), 117.11 (CH), 100.06 (quat.), 37.81 (N-CH2), 20.41 (Ar-CH3), 19.20 (CH2). MS: m/z (%) = 260 (20) [M+], 259 (18), 169 (91), 111 (76), 83 (49), 71 (100), (Found: C, 64.28; H, 5.96; N, 10.99. C14H16N2O3 requires C, 64.60; H, 6.20; N 10.76%).
    Crossref
  • 8b Jackman LM. Timothy F. J. Am. Chem. Soc.  1975,  97:  2811 
    CrossrefSearch in Google Scholar
7

General Procedure for Reactions of 2-( N -Methyl-anilino)-3-formylchromones (3a-c) with Aliphatic Diamines (Ethylenediamine and 1,3-Diaminopropane): 2-(N-Methylanilino)-3-formylchromones (3a-c, 1.0 mmol) were dissolved in acetonitrile-water (80:20, 50 mL) at reflux and the solutions of diamines (1.0 mmol) in acetonitrile (5 mL) were added to the above solutions. The contents were heated at reflux for 2 h, after which the solvent was evaporated under vacuum. The crude products were directly crystallized and recrystallized from acetone.